Last reviewed · How we verify
NCT06304077: REGaitVR
Restorative Environments for Gait Therapy with VR
NA trial testing Forest in Gait Analysis in 84 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | ETH Zurich |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 23 April 2024 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 3 locations across Switzerland |
Drugs / interventions tested
- Forest
- Urban
- Rural
Conditions studied
- Gait Analysis — all drugs for Gait Analysis →
- Virtual Reality — all drugs for Virtual Reality →
- Attention — all drugs for Attention →
- Stress — all drugs for Stress →
Sponsor
ETH Zurich — full company profile →
Who can join
65 and older, any sex, with Gait Analysis or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to investigate the effects of landscapes during gait therapy. The investigators will evaluate the impacts of restorative landscapes as they occur in urban, rural and forest environments. Older people will experience those landscapes using virtual reality (VR) goggles during their gait training. The investigators expect the landscapes to have an effect on the following three aspects: (1) stress reduction, (2) restoration of attention and (3) change in gait parameters. For this purpose, volunteers who are currently inpatient in one of our study centers and already participating in gait therapy will be assigned to a group. The control group will receive the standard therapy. The participants of the intervention groups will receive five additional VR training sessions to the standard therapy. In these sessions, the participants will walk through urban, rural and forest landscapes and perform balance improvement exercises. The five training sessions will take place within ten days. Allocation to the control or intervention groups and their landscapes is random. At the start and end of participation, tests defining stress levels and gait parameters are carried out so that comparisons can be made between before and after treatment. The goal of the study is to find out which type of landscape supports restoration and can therefore contribute to greater gait stability. The investigators expect that improved gait stability will be promoted by stress reduction and increased attention induced by the virtual environments. The investigators are investigating the consequences of repeated application of virtual landscapes and the relationship between the effect of the landscape and the preferences and habits of the study participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06304077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gait Analysis
Currently open trials in the same condition.
- NCT06994793 — Validity and Reliability of Gait and Jump Parameters Measured by the iSen Device in Healthy Adults · recruiting
Other ETH Zurich trials
Trials by the same sponsor.
- NCT07435766 — Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy · NA · recruiting
- NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
- NCT07119411 — ICU Background Early Awareness for Critical deterioratiON · not yet recruiting
- NCT06856291 — Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance · recruiting
- NCT06814327 — Assessment of Organ Failure Risk Predictions in ICU · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06304077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ETH Zurich
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06304077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing